Jörg Kaufmann
YOU?
Author Swipe
View article: 67P Lesion-based results of the non-small cell lung cancer (NSCLC) subgroup in the ARTIC trial: Abscopal effects in metastasized cancer patients treated with radiotherapy and immune checkpoint inhibition
67P Lesion-based results of the non-small cell lung cancer (NSCLC) subgroup in the ARTIC trial: Abscopal effects in metastasized cancer patients treated with radiotherapy and immune checkpoint inhibition Open
The abscopal effect (AbE) is a systemic immune response mediated by the effects of radiotherapy (RT) on the immune system. The AbE in patients with metastatic cancer treated with RT alone has been seen rarely, however, in the era of immune…
View article: Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
Purpose: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models. The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hem…
View article: Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 485K
View article: Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 477K
View article: Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 477K
View article: Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 174K
View article: Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 82K
View article: Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 82K
View article: Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 174K
View article: Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
Purpose: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models. The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hem…
View article: Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 485K
View article: Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
We have previously described a small interfering RNA (siRNA) delivery system (AtuPLEX) for RNA interference (RNAi) in the vasculature of mice. Here we report preclinical data for Atu027, a siRNA-lipoplex directed against protein kinase N3 …
View article: Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
We have previously described a small interfering RNA (siRNA) delivery system (AtuPLEX) for RNA interference (RNAi) in the vasculature of mice. Here we report preclinical data for Atu027, a siRNA-lipoplex directed against protein kinase N3 …
View article: Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression